TRUNCATE-TB Clinical Trial

The National University of Singapore is partnering with DLS HSI Research Division for the TRUNCATE-TB  trial.  TRUNCATE (Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis (TB)) is SPRINT-TB’s flagship clinical trial across multiple Asian countries evaluating the effectiveness of two-month treatment strategies for drug-sensitive TB. Funded by UK MRC/Wellcome Trust /DfID and Singapore NMRC, the trial includes treatment arms with novel combinations of established and new drugs that are currently in Phase 3 trials. The trial brings together a large team of clinicians, statisticians, microbiologists, and trial management staff across Asia and UK.